Drug Profile
Bevacizumab biosimilar - Kidswell Bio
Alternative Names: GBS-004Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Gene Techno Science
- Developer Kidswell Bio
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for research development in Cancer in Japan
- 11 Nov 2021 Bevacizumab biosimilar - Kidswell Bio is still in early research development in Cancer in Japan (Kidswell Bio pipeline, November 2021)
- 28 Aug 2021 No recent reports of development identified for research development in Cancer in Japan